Retrospective analysis of HDFN due to ABO incompatibility in a single institution over 6 years
© 2018 British Blood Transfusion Society..
OBJECTIVES: To study the rate of ABO haemolytic anaemia of fetus and newborn (HDFN) in one institution over 6 years.
BACKGROUND: ABO major incompatibility between mothers and their newborns occurs in about 10% of births. So, mothers with an O blood group may form IgG-class antibodies against A and B antigens, which could pass across the placenta and lead to a variable degree of HDFN in the newborn.
METHODS: At our institution, we have reviewed data regarding ABO-based HDFN in the last 6 years.
RESULTS: We found that, in 28 089 deliveries, an ABO major incompatibility between mothers and newborns occurs in 11% of cases, with 72% of O/A and 28% of O/B incompatibility. In turn, 23% of these newborns had an eluate-confirmed positive direct antiglobulin test [DAT; 74% (511) were due to anti-A and 26% (179) to anti-B], with 1·0% requiring invasive treatments (exchange transfusion or intravenous immunoglobulin). Overall, 2·5% of the total newborns had a positive DAT for an anti-A or anti-B antibody, and 0·11% required invasive treatment in addition to phototherapy for their HDFN.
CONCLUSIONS: Serological ABO HDFN is a relatively frequent event when an O-A/O-B incompatibility between mothers and their newborn occurs and, in most cases, translates into a self-limiting disease, with a small number of newborns requiring invasive treatments. The DAT test, although not predictive of disease severity, appears to be a useful tool to monitor babies born from O-A/O-B-incompatible pregnancies and to identify those who may require treatment.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2019 |
---|---|
Erschienen: |
2019 |
Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
---|---|
Enthalten in: |
Transfusion medicine (Oxford, England) - 29(2019), 3 vom: 26. Juni, Seite 197-201 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Matteocci, A [VerfasserIn] |
---|
Links: |
---|
Themen: |
ABO Blood-Group System |
---|
Anmerkungen: |
Date Completed 25.12.2019 Date Revised 25.12.2019 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1111/tme.12512 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM280299796 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM280299796 | ||
003 | DE-627 | ||
005 | 20231225025024.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2019 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1111/tme.12512 |2 doi | |
028 | 5 | 2 | |a pubmed24n0934.xml |
035 | |a (DE-627)NLM280299796 | ||
035 | |a (NLM)29369480 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Matteocci, A |e verfasserin |4 aut | |
245 | 1 | 0 | |a Retrospective analysis of HDFN due to ABO incompatibility in a single institution over 6 years |
264 | 1 | |c 2019 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 25.12.2019 | ||
500 | |a Date Revised 25.12.2019 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2018 British Blood Transfusion Society. | ||
520 | |a OBJECTIVES: To study the rate of ABO haemolytic anaemia of fetus and newborn (HDFN) in one institution over 6 years | ||
520 | |a BACKGROUND: ABO major incompatibility between mothers and their newborns occurs in about 10% of births. So, mothers with an O blood group may form IgG-class antibodies against A and B antigens, which could pass across the placenta and lead to a variable degree of HDFN in the newborn | ||
520 | |a METHODS: At our institution, we have reviewed data regarding ABO-based HDFN in the last 6 years | ||
520 | |a RESULTS: We found that, in 28 089 deliveries, an ABO major incompatibility between mothers and newborns occurs in 11% of cases, with 72% of O/A and 28% of O/B incompatibility. In turn, 23% of these newborns had an eluate-confirmed positive direct antiglobulin test [DAT; 74% (511) were due to anti-A and 26% (179) to anti-B], with 1·0% requiring invasive treatments (exchange transfusion or intravenous immunoglobulin). Overall, 2·5% of the total newborns had a positive DAT for an anti-A or anti-B antibody, and 0·11% required invasive treatment in addition to phototherapy for their HDFN | ||
520 | |a CONCLUSIONS: Serological ABO HDFN is a relatively frequent event when an O-A/O-B incompatibility between mothers and their newborn occurs and, in most cases, translates into a self-limiting disease, with a small number of newborns requiring invasive treatments. The DAT test, although not predictive of disease severity, appears to be a useful tool to monitor babies born from O-A/O-B-incompatible pregnancies and to identify those who may require treatment | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a ABO incompatibility | |
650 | 4 | |a ABO red cell antigens | |
650 | 4 | |a DAT | |
650 | 4 | |a haemolytic disease of fetus and newborn | |
650 | 4 | |a immune anti-A/anti-B IgG antibodies | |
650 | 7 | |a ABO Blood-Group System |2 NLM | |
650 | 7 | |a Isoantibodies |2 NLM | |
700 | 1 | |a De Rosa, A |e verfasserin |4 aut | |
700 | 1 | |a Buffone, E |e verfasserin |4 aut | |
700 | 1 | |a Pierelli, L |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Transfusion medicine (Oxford, England) |d 1992 |g 29(2019), 3 vom: 26. Juni, Seite 197-201 |w (DE-627)NLM012655937 |x 1365-3148 |7 nnns |
773 | 1 | 8 | |g volume:29 |g year:2019 |g number:3 |g day:26 |g month:06 |g pages:197-201 |
856 | 4 | 0 | |u http://dx.doi.org/10.1111/tme.12512 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 29 |j 2019 |e 3 |b 26 |c 06 |h 197-201 |